Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
ZTS - Zoetis Inc
-0.48(-0.29%)9:03:56 PM 1/30/2023
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets the products in approximately 45 countries, and sells the products in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. In the 1950s, Pfizer began research on several drugs including Oxytetracycline. John McKeen, a chemical engineer with Pfizer products, discovered its effective use in livestock. In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana called Vigo. By 1988 the division was renamed Pfizer Animal Health.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.
Stock Statistics
PE Ratio37.7
PEG Ratio3.0
P/S (ttm)12.6
Earning Growth (QoQ)32%
Revenue Growth (QoQ)
Short %1%
Held by Institutions %94%
1 Day Vol Adjusted Return-0.2
1 Month Vol Adjusted Return8.6
3 Month Vol Adjusted Return3.7
6 Month Vol Adjusted Return-4.6
20 Days SMA Price ZScore0.9
50 Days SMA Price ZScore1.7
12 -26 Days PPO2.9
1 Month Average Short Volume Ratio54.4
1 Day Volume Change ZScore-0.8
1 Month Daily Vol1.7
Related Topics
leak data

Related Topics


Stock news

    4 Top Stocks With High Dividend Growth to Buy in 2023 and Hold Forever

    These businesses offer powerful passive income potential, growing their dividends between 178% and 481% over the last five years.

    Zoetis (ZTS) Stock Sinks As Market Gains: What You Should Know

    Zoetis (ZTS) closed at $165.18 in the latest trading session, marking a -1.82% move from the prior day.

    UTHR vs. ZTS: Which Stock Is the Better Value Option?

    UTHR vs. ZTS: Which Stock Is the Better Value Option?

    Finance Chiefs Hope New Congress Will Revisit Tax Rule on R&D Expenses

    Companies are reporting higher taxable income amid a change in tax law that affects how they treat spending on research and development.

    If You Invested $5,000 in Zoetis in 2013, This Is How Much You Would Have Today

    When you're smooshing your dog's monthly heartworm pill into a dollop of peanut butter to make it more appetizing for Fido, there's a good chance that you're trying to get your pet to consume one of Zoetis' (NYSE: ZTS) products. Time was on your side if you bought shares of Zoetis in early 2013, right after its initial public offering (IPO). In short, your $5,000 investment in Zoetis from 10 years ago would now be worth just under $25,500, marking a gain of around 410%.

    3 Reasons to Buy Zoetis, and 1 Reason to Sell

    Whether you're a doting dog mom or a steely-eyed cattle rancher, you'll probably agree that animals need healthcare, just as we do. Enter Zoetis (NYSE: ZTS), a multinational pharmaceutical player that caters exclusively to developing medicines and other healthcare goods for pets and livestock. Thanks to its long history of developing and selling everything from pet pain pills to diagnostic hardware for veterinary clinics, this company has a lot to offer for investors of all stripes.

    Why Zoetis Stock Lost 40% in 2022

    Shares of Zoetis (NYSE: ZTS) were losing ground in 2022 as the pet pharmacist saw headwinds related to a slowdown in the pet sector. A compression in valuations in growth stocks due to rising interest rates also led investors to move money into bonds and safer stocks. According to data from S&P Global Market Intelligence, the stock finished 2022 down 40%.

    COLL vs. ZTS: Which Stock Is the Better Value Option?

    COLL vs. ZTS: Which Stock Is the Better Value Option?

    These 3 Stocks Crashed by 40% in 2022. But Analysts Remain Bullish On Them

    Last year was an awful one for many growth stocks. Three stocks that struggled mightily last year that analysts think can soar include Zoetis (NYSE: ZTS), Amazon (NASDAQ: AMZN), and Take-Two Interactive (NASDAQ: TTWO). Last year was a brutal one for animal health company Zoetis as its shares dropped a staggering 40%.

    Is Zoetis Stock a Buy?

    Zoetis' business is generally stable and very consistent -- but the same can't be said for its struggling stock.